Immunopotentiators in modern vaccines
著者
書誌事項
Immunopotentiators in modern vaccines
Elsevier Academic Press, c2006
大学図書館所蔵 全1件
  青森
  岩手
  宮城
  秋田
  山形
  福島
  茨城
  栃木
  群馬
  埼玉
  千葉
  東京
  神奈川
  新潟
  富山
  石川
  福井
  山梨
  長野
  岐阜
  静岡
  愛知
  三重
  滋賀
  京都
  大阪
  兵庫
  奈良
  和歌山
  鳥取
  島根
  岡山
  広島
  山口
  徳島
  香川
  愛媛
  高知
  福岡
  佐賀
  長崎
  熊本
  大分
  宮崎
  鹿児島
  沖縄
  韓国
  中国
  タイ
  イギリス
  ドイツ
  スイス
  フランス
  ベルギー
  オランダ
  スウェーデン
  ノルウェー
  アメリカ
注記
Includes bibliographical references and index
内容説明・目次
内容説明
Immunopotentiators in Modern Vaccines provides an in-depth insight and overview of a number of most promising immunopotentiators in modern vaccines. In contrast to existing books on the subject it provides recent data on the critical mechanisms governing the activity of vaccine adjuvants and delivery systems. Knowledge of immunological pathways and scenarios of the cells and molecules involved is described and depicted in comprehensive illustrations.
目次
Preface
List of contributors
Part I: Perspective on immunological mechanisms underlying adjuvant activity
Chapter 1: Unraveling aEUROoethe immunologist's dirty little secretaEURO
Part II: Host-derived immunopotentiators
Chapter 2: Dendritic cells as targets and tools in vaccines
Chapter 3: Host-derived molecules as adjuvants
Part III: Natural and synthetic immunopotentiators
Chapter 4: Innate immune mechanisms and the identification of immune potentiators as vaccine adjuvants
Chapter 5: CpG oligodeoxynucleotides as vaccine adjuvants
Chapter 6: Toll-like receptor 4 agonists as vaccine adjuvants
Chapter 7: Immunomodulatory adjuvants from Quillaja saponaria
Part IV: Particulate immunopotentiators and delivery systems
Chapter 8: Microparticles as vaccine delivery systems
Chapter 9: MF59: a safe and potent adjuvant for human use
Chapter 10: Development and evaluation of AS04, a novel and improved adjuvant system containing MPL and aluminum salt
Chapter 11: Virosomes for vaccine delivery
Chapter 12: The ISCOMATRIXa"c adjuvant
Chapter 13: Mineral adjuvants
Part V: Mucosal/nonparenteral adjuvants
Chapter 14: Mucosal adjuvants based on cholera toxin and E. coli heat-labile enterotoxin
Chapter 15: Transcutaneous immunization using the heat-labile enterotoxin of E. coli as an adjuvant
Part VI: Th-1/CTL adjuvants
Chapter 16: T cell adjuvants and novel strategies for their identification
Part VII: Adjuvants in noninfectious disease vaccines
Chapter 17: Vaccination to treat noninfectious diseases: surveying the opportunities
Part VIII: Clinical practice
Chapter 18: Clinical evaluation of adjuvants
Chapter 19: Regulatory considerations in the nonclinical safety assessment of adjuvanted preventive vaccines
Index
「Nielsen BookData」 より